5
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Clinical and Serological Follow-up of Patients with Polyarthritis, Raynaud's Phenomenon, and Circulating RNP Antibodies

&
Pages 51-56 | Received 06 Jan 1989, Published online: 12 Jul 2009
 

Abstract

Fourteen patients with polyarthritis, Raynaud's phenomenon/sclerodactyly, and circulating (U1)RNP antibodies were followed up for 10 years. All patients could be classified as having the mixed connective tissue disease at the end of the follow-up. The immunoblotting analysis revealed marked heterogeneity in the ribonucleoprotein antibody profiles. The antibodies were mainly of the IgG isotype but in four sera only IgA and/or IgM type antibodies were demonstrated. Three patients who were found to have anti-RNP by the immunodiffusion assay proved negative for anti-U-RNP antibodies by immunoblotting. Patients with antibodies against the BB' polypeptides of U-RNP particles had a disease characterized by non-erosive arthritis, sclerodactyly and cutaneous manifestations. Patients who had antibodies against the 70 kD polypeptide of U1-RNP particles only had an erosive polyarthritis. However, these patients did not tolerate treatment with either gold salts or with D-penicillamine. Thus, the classification of the RNP antibodies by immunoblotting technique seemed to define patient groups whose disease took differing courses.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.